Cargando…

Implication of VEGFR2 Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study

Background: This study aimed to investigate the implication of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) polymorphism on the prognosis of anlotinib monotherapy among patients with treatment-refractory advanced nonsmall cell lung cancer (NSCLC). Methods: Designed as a retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaoyuan, Cheng, Yang, Zhu, Baorang, Geng, Ming, Yan, Peng, Hu, Mu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047798/ https://www.ncbi.nlm.nih.gov/pubmed/35443836 http://dx.doi.org/10.1177/15330338221080993

Ejemplares similares

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma
por: Yao, Weitao, et al.
Publicado: (2022)

Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy
por: Chen, Tian, et al.
Publicado: (2022)

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Tang, Mengqiu, et al.
Publicado: (2021)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
por: Kucharczyk, Tomasz, et al.
Publicado: (2015)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study
por: Jiang, Hong-Tao, et al.
Publicado: (2021)

Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study
por: Li, Yonghui, et al.
Publicado: (2022)

Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study
por: Yin, Jun, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor
por: Cheng, Jian-De, et al.
Publicado: (2020)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
por: Hu, Wen-Xia, et al.
Publicado: (2022)

Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis
por: Yu, Guocan, et al.
Publicado: (2020)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
por: Song, Fei, et al.
Publicado: (2020)

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling
por: Qin, Tingting, et al.
Publicado: (2020)

Prognostic value of prognostic nutritional index and its variations in advanced non‐small‐cell lung cancer patients treated with anlotinib monotherapy
por: Chen, Tian, et al.
Publicado: (2022)

Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC
por: Kaira, Kyoichi, et al.
Publicado: (2022)

RAGE Genetic Polymorphisms Are Associated with Risk, Chemotherapy Response and Prognosis in Patients with Advanced NSCLC
por: Wang, Xiang, et al.
Publicado: (2012)

Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib
por: Chen, Tian, et al.
Publicado: (2022)

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
por: Chi, Yihebali, et al.
Publicado: (2023)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
por: Wang, Chang-Lu, et al.
Publicado: (2022)

Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
por: Jia, Wenqing, et al.
Publicado: (2022)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
por: Ni, Jing, et al.
Publicado: (2020)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
por: Sun, Yongkun, et al.
Publicado: (2016)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
por: Wang, Jingyi, et al.
Publicado: (2023)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jm665j4frl20nm9unu585gfu63